MYRIAD GENETICS, INC.
NASDAQ: MYGN
▲
26.71
+0.91
+3.53%
1 Day
-
Open
25.52
-
Previous Close
25.80
-
Volume (Avg)
806.74k (995.39k)
-
Day's Range
25.52-27.00
-
52Wk Range
9.24-30.13
-
Market Cap.
1.88B
-
Dividend Rate ( Yield)
-
-
Beta
1.73
-
Shares Outstanding
75.21M
-
P/E Ratio (EPS)
581.41 (-)
Top Stories
-
Myriad Genetics (MYGN), Illumina Partner to Enhance Oncology Arm
Zacks.com 4 days ago -
Myriad Genetics Up on Strategic-Options Plan for Autoimmune Unit
TheStreet -
Stocks making the biggest moves after the bell: Cal-Maine Foods, Myriad Genetics & more
CNBC -
The Daily Biotech Pulse: Aerpio Reviews Strategic Options, Hologic Goes Shopping
Benzinga -
Myriad Genetics Forms Strategic Partnership with Illumina in Oncology
Nasdaq 4 days agoMyriad Genetics, Inc., a leader in genetic testing and precision medicine, today announced a strategic collaboration with Illumina, Inc. for Illumina to create a kit-based version of the myChoice ® companion diagnostic test for international markets.
-
Myriad Genetics (MYGN), Illumina Partner to Enhance Oncology Arm
Nasdaq -
Myriad Genetics Provides Transformation Update, Pursues Strategic Alternatives for Autoimmune Business, Realigns International Operations
Business Insider -
Myriad Genetics Up on Strategic-Options Plan for Autoimmune Unit
TheStreet.com -
Developing Countries To Drive Growth In The Human Genetics Market- Myriad Genetics, QIAGEN, Agilent Technologies, Thermo Fisher Scientific
ARN -
Illumina Announces New and Expanded Oncology Partnerships with Bristol Myers Squibb, Kura Oncology, Myriad Genetics, and Merck to Advance Comprehensive Genomic Profiling
Business Wire -
Myriad Genetics CEO Paul J. Diaz to Present at 39th Annual J.P. Morgan Healthcare Conference
Associated Press -
Stocks making the biggest moves after the bell: Cal-Maine Foods, Myriad Genetics & more
CNBC -
MYGN Jan 2021 50.000 call
Yahoo Finance -
Myriad Genetics Forms Strategic Partnership with Illumina in Oncology
Morningstar%2c Inc. -
Myriad Genetics Provides Transformation Update, Pursues Strategic Alternatives for Autoimmune Business, Realigns International Operations
Morningstar%2c Inc. 1/5/2021SALT LAKE CITY, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the substantial completion of its ...
-
Myriad Genetics CEO Paul J. Diaz to Present at 39th Annual J.P. Morgan Healthcare Conference
Stockhouse -
MYGN Jan 2021 12.000 call
Yahoo Finance -
Myriad Genetics Forms Strategic Partnership with Illumina in Oncology
Business Insider
![image beacon](https://web.vortex.data.msn.com/collect/v1/t.gif?name=%27Ms.Webi.PageView%27&ver=%272.1%27&appId=%27JS%3AMSN%27&ext-app-env=%27prod%27&ext-javascript-libver=%274.0.0-beta-10%27&ext-user-localId=%27t%3A1AAF265FB636682830F2299EB7316902%27&*baseType=%27Ms.Content.PageView%27&*isJs=False&*title=%27%27&*isLoggedIn=False&*isManual=True&*serverImpressionGuid=%270072e11a-fd45-45a4-8047-c78e6555ef09%27&-ver=%271.0%27&-impressionGuid=%270072e11a-fd45-45a4-8047-c78e6555ef09%27&-pageName=%27stocksummary%27&-uri=%27http%253A%252F%252Fwww.msn.com%252Fen-us%252Fmoney%252Fstockdetails%252Ffi-a1y7jc%253FSymbol%253DMYGN%27&-referrerUri=%27%27&-pageTags=%27{"pg.t"%3A"data"%2C"pg.p"%3A"prime"%2C"pg.c"%3A""%2C"ex"%3A""%2C"rid"%3A"0072e11afd4545a48047c78e6555ef09"%2C"clid"%3A"1AAF265FB636682830F2299EB7316902"%2C"clidType"%3A"muid"%2C"di"%3A"7290"%2C"partner"%3A"Thomson%2BReuters"%2C"publcat"%3A"Thomson%2BReuters%252c%2BLLC"%2C"cvs"%3A"Browser"%2C"subcvs"%3A"finance"%2C"entityId"%3A"a1y7jc"%2C"entitySrc"%3A"fi"%2C"provid"%3A"AAf3a78"%2C"dpt"%3A"stockdetails"%2C"sdpt"%3A""%2C"ar"%3A"0"%2C"dgk"%3A"downlevel.pc"%2C"imd"%3A"0"%2C"parentId"%3A""%2C"pgIdx"%3A""%2C"pgTot"%3A""%2C"anoncknm"%3A""%2C"afd"%3A""%2C"issso"%3A"0"%2C"aadState"%3A"0"}%27&-behavior=0&-market=%27en-us%27){kind=small}